An interventional study of Hypervision proton surgery in Non-Small Cell Lung Cancer, sponsored by Anhui Provincial Cancer Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-13.
Sponsored by Anhui Provincial Cancer Hospital · Not applicable, Interventional, and Treatment
This study was a single-center, single-arm clinical study to evaluate the safety and efficacy of hypervision proton surgery with single large fractionated doses (34GyE and 39GyE) in the treatment of early peripheral NSCLC.
This study adopted a dose escalation protocol (an improved "two-stage two-dose group" design) to explore the safety and efficacy of visual proton surgery (single large fractionated doses of 34GyE and 39GyE) in the treatment of early peripheral NSCLC.
6,488 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,632 are open to participants now.
This study's planned enrollment of 12 is below the median of 62 across 5,213 interventional studies indexed under Carcinoma, Non-Small-Cell Lung.
Browse Carcinoma, Non-Small-Cell Lung studies →Anhui Provincial Cancer Hospital is the lead sponsor of 24 studies on the registry; 20 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Proton radiotherapy 34GyE/f or 39GyE/f
Radiation: Hypervision proton surgery
Proton radiaotherapy (34GyE or 39GyE)
The incidence of grade ≥ 3 psAEs at 1 month
Radiation induced adverse events according to the Common Terminology Criteria for Adverse Events (CTCAE)
Time frame: 1 month after proton radiotherapy
The incidence of grade ≥ 3 psAEs at 1 year
Radiation induced adverse events according to the Common Terminology Criteria for Adverse Events (CTCAE)
Time frame: 1 year after proton radiotherapy
Primary tumor control at 1 year
Primary tumor control at 1 year
Time frame: 1 year after proton radiotherapy
Disease-free survival time
Disease-free survival time
Time frame: From date of treatment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months
Overall survival time
Overall survival time
Time frame: From date of treatment until the date of death
Plan to share: Undecided
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Carcinoma, Non-Small-Cell Lung→
Anhui Provincial Cancer Hospital